- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.12.24 | BullFrog AI Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 27.12.24 | BullFrog AI Holdings, Inc.: BullFrog AI Issues Letter to Stockholders | 120 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Dec. 27, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial... ► Artikel lesen | |
| 17.12.24 | BullFrog AI names Josh Blacher as its CFO | 1 | Seeking Alpha | ||
| 17.12.24 | BullFrog AI Holdings, Inc.: BullFrog AI Announces Appointment of Chief Financial Officer | 133 | GlobeNewswire (Europe) | GAITHERSBURG, Md., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial... ► Artikel lesen | |
| 12.12.24 | BullFrog AI Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 25.11.24 | BullFrog AI Holdings, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 08.11.24 | Bullfrog AI Holdings files secondary offering of common stock underlying warrants | 2 | Seeking Alpha | ||
| BULLFROG AI Aktie jetzt für 0€ handeln | |||||
| 08.11.24 | BullFrog AI Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.11.24 | BullFrog AI Holdings, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 25.10.24 | Bullfrog AI Holdings, Inc. (BFRG) to Showcase Breakthrough AI-Driven Drug Discovery Innovations at Google's Inaugural Cancer AI Symposium | 5 | Insider Monkey | ||
| 22.10.24 | BullFrog AI Holdings, Inc.: BullFrog AI's VP Artificial Intelligence to Present at Google's Cancer AI Symposium | 2 | GlobeNewswire (USA) | ||
| 21.10.24 | BullFrog AI Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.10.24 | BullFrog AI Holdings, Inc.: Bullfrog AI Announces Closing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million | 2 | GlobeNewswire (USA) | ||
| 18.10.24 | BullFrog AI announces registered direct offering | 2 | Investing.com | ||
| 18.10.24 | BullFrog AI kündigt registrierte Direktplatzierung an | 1 | Investing.com Deutsch | ||
| 18.10.24 | BullFrog AI Holdings, Inc.: Bullfrog AI Announces Pricing of Registered Direct Offering and Concurrent Private Placement for Aggregate Gross Proceeds of $3.13 Million | 1 | GlobeNewswire (USA) | ||
| 15.10.24 | BullFrog AI Holdings, Inc.: BullFrog AI Strengthens Scientific Advisory Board with the Addition of GSK Veteran and Industry Pioneer Dr. John Baldoni | 5 | GlobeNewswire (USA) | ||
| 09.10.24 | BullFrog AI Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.10.24 | BullFrog AI Holdings, Inc.: BullFrog AI Announces Publication of Data Supporting Potential of Liver Disease Treatment Candidate BF-114 | 14 | GlobeNewswire (USA) | ||
| 09.10.24 | Vininder Singh Sells 5,911 Shares of Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) Stock | 6 | MarketBeat |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 1,840 | -0,76 % | Fast 200 % Kurspotenzial! Nel ASA, Evotec, BioNTech, Medigene Aktien! | Die Aktie von Medigene hat mit dem Turnaround begonnen. Neben positiven Patent-News aus Japan für das Krebs-Testis-Antigen MAGE-A4 treibt eine Kaufempfehlung das Wertpapier. So sehen Analysten mehr... ► Artikel lesen | |
| BB BIOTECH | 40,500 | +0,87 % | EQS-News: BB BIOTECH AG: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag | EQS-News: BB BIOTECH AG
/ Schlagwort(e): Jahresergebnis/Dividende
BB Biotech: Vorläufige Jahresergebnisse 2024 und Dividendenvorschlag
24.01.2025 / 07:00 CET/CEST
Für... ► Artikel lesen | |
| QIAGEN | 43,595 | -0,34 % | Biotech Report: Qiagen behauptet, Evotec leichter | (shareribs.com) Frankfurt 20.01.2025 - Die Biotechnologie-Aktien tendierten im deutschen Handel überwiegend schwächer. Die Marktteilnehmer halten sich zurück, da Trump in den USA seine nächste Amtszeit... ► Artikel lesen | |
| NOVAVAX | 8,789 | +0,09 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| STRYKER | 377,90 | +0,61 % | Strong Segmental Performance to Drive Stryker's Q4 Earnings? | ||
| ILLUMINA | 130,58 | +0,62 % | Inside the New Illumina MiSeq i100 Series: The Making of the Software | What's it like to build the software in a brand-new sequencer? Illumina's Aneesh Natarajan takes us on the journeyOriginally published on Illumina News Center NORTHAMPTON, MA / ACCESS Newswire / January... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 39,800 | -3,86 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results | -CASGEVY approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada- -45 authorized... ► Artikel lesen | |
| AAP IMPLANTATE | 1,860 | -1,06 % | aap Implantate: Umsatzwachstum von 6,3 Prozent in 2024 | Die aap Implantate AG hat im Geschäftsjahr 2024 vorläufigen Angaben vom Freitag zufolge ein Umsatzwachstum von 6,3 Prozent auf 12,2 Millionen Euro erzielt. Man habe den operative Cashflow unter anderem... ► Artikel lesen | |
| OCUGEN | 0,711 | -4,11 % | Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 | OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 1,119 | +0,83 % | Expert Outlook: Sangamo Therapeutics Through The Eyes Of 11 Analysts | ||
| INTELLIA THERAPEUTICS | 9,830 | -6,02 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema | CAMBRIDGE, Mass., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| SCORPIUS | 0,274 | 0,00 % | XFRA 1HB0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCORP.HLDGS.NEW... ► Artikel lesen | |
| EDITAS MEDICINE | 1,348 | +2,82 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,190 | -1,51 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Preliminary Full Year 2024 ORLADEYO (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) | -ORLADEYO net revenue expected to be between $515-$535 million in 2025- -Total revenue (including RAPIVAB®) expected to be between $540-$560 million in 2025- -Company achieved operating profit in... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,700 | +26,35 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen |
Das Unternehmen BULLFROG AI HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,070 (-2,94 %) liegt der Kurs bei 2,310 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BULLFROG AI HOLDINGS INC finden Sie auf Wallstreet Online.
